References
- 1ThenganattMAJankovicJRecent advances in understanding and managing Tourette syndromeF1000Research20165152doi: 10.12688/f1000research.7424.1
- 2American Psychiatric AssociationDiagnostic and statistical manual of mental disorders5th ed.Arlington, VAAmerican Psychiatric Publishing2013
- 3GilbertDLJankovicJPharmacological treatment of Tourette syndromeJ Obsessive Compuls Relat Disord20143407414doi: 10.1016/j.jocrd.2014.04.006
- 4JankovicJTherapeutic developments for tics and myoclonusMov Disord20153015661573doi: 10.1002/mds.2641426315614
- 5ViswanathanAJimenez-ShahedJBaizabal CarvalloJFJankovicJDeep brain stimulation for Tourette syndrome: target selectionStereotact Funct Neurosurg201290213224doi: 10.1159/00033777622699684
- 6KefalopoulouZZrinzoLJahanshahiMet alBilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trialLancet Neurol201514595605doi: 10.1016/S1474-4422(15)00008-325882029
- 7JainSGreenePEFruchtSJTetrabenazine treatment of pediatric hyperkinetic disordersMov Disord20062119661971doi: 10.1002/mds.2106316958131
- 8KenneyCHunterCNMJankovicJTetrabenazine in the treatment of Tourette syndromeJ Pediatric Neurol20075913
- 9PortaMSassiMCavallazziMFornariMBrambillaAServelloDTourette’s syndrome and role of tetrabenazine: review and personal experienceClin Drug Investig200828443doi: 10.2165/00044011-200828070-00006
- 10JankovicJBeachJLong-term effects of tetrabenazine in hyperkinetic movement disordersNeurology199748358362doi: 10.1212/WNL.48.2.3589040721
- 11BurkeRERechesATraubMMIlsonJSwashMFahnSTetrabenazine induces acute dystonic reactionsAnn Neurol198517200202doi: 10.1002/ana.4101702173977303
- 12JanikPFiguraMTetrabenazine-induced oculogyric crisis—a rare complication in the treatment of Gilles de la Tourette SyndromeNeuropsychiatr Dis Treat201612497499doi: 10.2147/NDT.S9869426955276
- 13MehannaRHunterCDavidsonAJimenez-ShahedJJankovicJAnalysis of CYP2D6 genotype and response to tetrabenazineMov Disord201328210215doi: 10.1002/mds.2527823280482
- 14HowlandRHDeuterated drugsJ Psychosoc Nurs Ment Health Serv2015531316
- 15StamlerDBradburyMBrownFThe pharmacokinetics and safety of deuterated-tetrabenazineNeurology201380P07210
- 16Tetrabenazine Medication GuideWashington DCPrestwick Pharmaceuticals2008http://www.xenazineusa.com/HCP/PrescribingXenazine.
- 17Huntington Study GroupFrankSTestaCMStamlerDEffect of Deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trialJAMA201653164050doi: 10.1001/jama.2016.865527380342
- 18LeckmanJFRiddleMAHardinMTet alThe Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severityJ Am Acad Child Adolesc Psychiatry198928566573doi: 10.1097/00004583-198907000-000152768151
- 19LeckmanJFTowbinKEOrtSIet alClinical assessment of tic disorder severityCohenDJeditorTourette’s syndrome and tic disordersNew York, NYJohn Wiley & Sons1988550578
- 20KamperSJMaherCGMackayGGlobal rating of change scales: a review of strengths and weaknesses and considerations for designJ Man Manip Ther200917163170doi: 10.1179/jmt.2009.17.3.16320046623
- 21JeonSWalkupJTWoodsDWet alDetecting a clinically meaningful change in tic severity in Tourette syndrome: a comparison of three methodsContemp Clin Trials201336414420doi: 10.1016/j.cct.2013.08.01224001701
- 22PeñaMSYalthoTCJankovicJTardive dyskinesia and other movement disorders secondary to aripiprazoleMov Disord201126147152doi: 10.1002/mds.2340220818603
- 23WalnOJankovicJAn update on tardive dyskinesia: from phenomenology to treatmentTremor Other Hyperkinet Mov20133doi: 10.7916/D88P5Z71
- 24VijayakumarDJankovicJDrug-induced dyskinesia, part 2: treatment of tardive dyskinesiaDrugs201676779787doi: 10.1007/s40265-016-0568-127091214
- 25Muller-VahlKRKrugerDDoes Tourette syndrome prevent tardive dyskinesia?Movement Disord20112624422444doi: 10.1002/mds.2389421956454
- 26JankovicJClarence-SmithKTetrabenazine for the treatment of chorea and other hyperkinetic movement disordersExpert Rev Neurother20111115091523doi: 10.1586/ern.11.14922014129
- 27MüllerTValbenazine granted breakthrough drug status for treating tardive dyskinesiaExpert Opin Investig Drugs201524737742doi: 10.1517/13543784.2015.1029573
- 28O’BrienCFJimenezRHauserRAet alNBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled studyMov Disord20153016811687doi: 10.1002/mds.2633026346941
- 29WijemanneSWuLJJankovicJLong-term efficacy and safety of fluphenazine in patients with Tourette syndromeMov Disord201429126130doi: 10.1002/mds.2569224150997
- 30JankovicJJimenez-ShahedJBrownLWA randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndromeJ Neurol Neurosurg Psychiatry2010817073doi: 10.1136/jnnp.2009.18534819726418
- 31YooHKJoungYSLeeJSet alA multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorderJ Clin Psychiatry201374e772780doi: 10.4088/JCP.12m0818924021518
- 32GunduzAOkunMSA review and update on Tourette syndrome: where is the field headed?Curr Neurol Neurosci Rep20161637doi: 10.1007/s11910-016-0633-x26936259